Quantcast
Last updated on April 18, 2014 at 9:36 EDT

Latest tumour Stories

2014-04-08 08:31:39

OICR's catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May TORONTO, April 8, 2014 /PRNewswire/ - People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR). The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over...

2014-04-08 08:30:08

CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin,...

2014-01-16 04:20:52

New collaboration aims to push cancer diagnostics to the next level SINGAPORE, Jan. 16, 2014 /PRNewswire/ -- A collaboration between National Cancer Centre Singapore (NCCS) and Clearbridge BioMedics, in partnership with the Pathology Department at Singapore General Hospital (SGH) has resulted in the establishment of the region's first Circulating Tumour Cell Centre of Research Excellence (CTC CoRE). This new Centre facilitates the use of circulating tumour cells (CTCs)[1] in...

2013-11-11 08:27:57

MELBOURNE, Australia and HAMBURG, Germany, Nov. 11, 2013 /PRNewswire/ -- -- Novel drug which improves visualisation and resection of malignant brain tumours now widely available -- Twice as many patients are without progression of brain cancer six months after surgery with GLIOLAN -- To date over 100 Australian patients have been treated with GLIOLAN via the Federal Government's Special Access Scheme A novel drug which assists neurosurgeons to better...

2013-09-30 15:52:49

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress (ECC2013). Cediranib, which is taken in pill form, is an inhibitor of a cell signalling process involved in formation of tumour blood vessels, essential for tumour growth, and it is the first oral inhibitor of its kind to show an improvement in the time...

2013-09-19 16:59:24

A piece of research submitted by the Artificial Intelligence and Approximate Reasoning Group (GIARA) of the NUP/UPNA-Public University of Navarre received an award from the European Association of Fuzzy Logic and Soft Computing (EUSFLAT) during its biennial meeting (EUSFLAT 2013) held in Milan last week. The researchers have developed a method that improves the delimitation of tumours in medical images. As they explained, “when the doctor decides where tumour tissue should be separated from...

2013-09-18 08:28:45

- Primary endpoint achieved while still recruiting SYDNEY, Sept. 18, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) has achieved the primary endpoint in its Phase 2 clinical trial of CAVATAK(TM) in the treatment of late stage melanoma patients (the CALM study). The Phase 2 trial is a single arm study being conducted at 10 US sites and is designed to investigate the safety and efficacy of intratumoral CAVATAK(TM) (Coxsackievirus A21) in 54 evaluable(1)...

2013-09-09 08:26:34

CALGARY, Sept. 9, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles. Of 25...

2013-08-22 08:26:42

Expansion offers key international markets innovative, thorough biomarker analysis to improve care for cancer patients IRVING, Texas, Aug. 22, 2013 /PRNewswire/ -- Caris Life Sciences(TM), a leading biosciences company focused on fulfilling the promise of personalized medicine in oncology, has signed a distribution agreement with IPS Genomix to facilitate patient access to its tumour profiling service, Molecular Intelligence(TM), in select Middle Eastern and African markets. Given...

2013-03-04 10:27:22

New research in the Journal of Clinical Investigation reveals that tumours in melanoma patients deliberately create conditions that knock out the body's 'premier' immune defence and instead attract a weaker immune response unable to kill off the tumour's cancerous cells. The study also highlights a potential antibody biomarker that could help predict prognosis and identify which patients are most likely to respond to specific treatments. The research, led by Dr Sophia Karagiannis and...